Outpatient treatment of pneumonia in a setting with and without an infectious disease doctor.

Marija Kusulja, Maša Žarković, Nikola Kudoić, Monika Mudrovčić, Natalija Sovina Stražičić, Ivan Gornik, Vladimir Krajinović
Author Information
  1. Marija Kusulja: Marija Kusulja, Dr Fran Mihaljević University Hospital for Infectious Diseases, Mirogojska 8, 10 000 Zagreb, Croatia, mkusulja@kusulja.com.

Abstract

AIM: To compare the outpatient treatment of community acquired pneumonia (CAP) by infectious disease doctors (IDDs) and doctors of other specialties (nIDDs).
METHODS: We retrospectively identified 600 outpatients with CAP: 300 treated by IDDs and 300 by nIDDs in two tertiary hospitals during 2019. The two groups were compared in terms of adherence to guidelines, antibiotic group prescription, frequency of combined treatment, and treatment duration.
RESULTS: IDDs prescribed significantly more first-line treatment (P<0.001) and alternative treatment (P=0.008). NIDDs prescribed more reasonable (P<0.001) and unnecessary (P=0.002) second-line treatment, and inadequate treatment (P=0.004). IDDs significantly more frequently prescribed amoxicillin (P<0.001) for typical and doxycycline (P=0.045) for atypical CAP, while nIDDs significantly more frequently prescribed amoxicillin-clavulanate (P<0.001) for typical and fluoroquinolones for both typical (P<0.001) and atypical (P<0.001) CAP. No significant differences were found in the frequency of combined treatment, which exceeded 50% in both groups, or in treatment duration.
CONCLUSIONS: Outpatient treatment of CAP in the absence of IDDs meant more broad-spectrum antibiotic prescription and more disregard for national guidelines. Our results highlight the need for antibiotic stewardship, especially in settings with no IDDs.

References

  1. Open Forum Infect Dis. 2022 Aug 01;9(8):ofac388 [PMID: 36004311]
  2. Infect Control Hosp Epidemiol. 2022 May;43(5):576-581 [PMID: 33993897]
  3. Lancet Infect Dis. 2017 Apr;17(4):411-421 [PMID: 28130063]
  4. Pharmacotherapy. 2016 Jun;36(6):679-93 [PMID: 27138564]
  5. Am J Infect Control. 2008 May;36(4):283-90 [PMID: 18455049]
  6. J Antimicrob Chemother. 2016 Jul;71(7):2047-51 [PMID: 27055759]
  7. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67 [PMID: 31573350]
  8. Eur J Emerg Med. 2023 Apr 1;30(2):102-109 [PMID: 35758267]
  9. Dtsch Arztebl Int. 2017 Dec 8;114(49):838-848 [PMID: 29271341]
  10. J Bras Pneumol. 2018 Sep-Oct;44(5):405-423 [PMID: 30517341]
  11. Acad Emerg Med. 2013 Sep;20(9):957-60 [PMID: 24033659]
  12. Infect Control Hosp Epidemiol. 2022 Jul 13;:1-10 [PMID: 35822429]
  13. PLoS One. 2020 Nov 4;15(11):e0241760 [PMID: 33147269]
  14. Infect Dis (Lond). 2018 Feb;50(2):107-116 [PMID: 28789580]
  15. Eur Respir J. 2011 Dec;38(6):1250-1 [PMID: 22130759]
  16. Clin Med Insights Circ Respir Pulm Med. 2014 Sep 14;8:17-20 [PMID: 25249765]

MeSH Term

Humans
Outpatients
Retrospective Studies
Pneumonia
Communicable Diseases
Amoxicillin
Anti-Bacterial Agents

Chemicals

Amoxicillin
Anti-Bacterial Agents

Word Cloud

Created with Highcharts 10.0.0treatmentIDDsP<0001CAPprescribedP=0nIDDsantibioticsignificantlytypicalpneumoniainfectiousdiseasedoctors300twogroupsguidelinesprescriptionfrequencycombineddurationfrequentlyatypicalOutpatientAIM:compareoutpatientcommunityacquiredspecialtiesMETHODS:retrospectivelyidentified600outpatientsCAP:treatedtertiaryhospitals2019comparedtermsadherencegroupRESULTS:first-linealternative008NIDDsreasonableunnecessary002second-lineinadequate004amoxicillindoxycycline045amoxicillin-clavulanatefluoroquinolonessignificantdifferencesfoundexceeded50%CONCLUSIONS:absencemeantbroad-spectrumdisregardnationalresultshighlightneedstewardshipespeciallysettingssettingwithoutdoctor

Similar Articles

Cited By